El Helali, A, Plummer, R, Jayson, G C, Coyle, V M, Drew, Y, Mescallado, N, Harris, N, Clamp, A R, McCann, J, Swaisland, H, Kennedy, R D, Cranston, A N & Wilson, R H 2022, ' A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours ', British Journal of Cancer . https://doi.org/10.1038/s41416-022-01780-z
Mateo, J, Moreno, V, Gupta, A, Kaye, S B, Dean, E, Middleton, M R, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S & Molife, L R 2016, ' An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib ', Targeted oncology . https://doi.org/10.1007/s11523-016-0435-8
Clinical Therapeutics, 38, 10, pp. 2286-2299 Dirix, L, Swaisland, H, Verheul, H M W, Rottey, S, Leunen, K, Jerusalem, G, Rolfo, C, Nielsen, D, Molife, L R, Kristeleit, R, de Vos-Geelen, J, Mau-Sorensen, M, Soetekouw, P, van Herpen, C, Fielding, A, So, K, Bannister, W & Plummer, R 2016, ' Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies ', Clinical Therapeutics, vol. 38, no. 10, pp. 2286-2299 . https://doi.org/10.1016/j.clinthera.2016.08.010 Clinical Therapeutics, 38, 2286-2299 Clinical therapeutics Clinical Therapeutics, 38(10), 2286-2299. Excerpta Medica